|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LMAN2L |
Gene summary for LMAN2L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LMAN2L | Gene ID | 81562 |
| Gene name | lectin, mannose binding 2 like | |
| Gene Alias | MRT52 | |
| Cytomap | 2q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006457 | UniProtAcc | Q9H0V9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81562 | LMAN2L | LZE4T | Human | Esophagus | ESCC | 6.01e-05 | 2.55e-01 | 0.0811 |
| 81562 | LMAN2L | LZE8T | Human | Esophagus | ESCC | 1.67e-02 | 8.95e-02 | 0.067 |
| 81562 | LMAN2L | LZE24T | Human | Esophagus | ESCC | 4.03e-08 | 1.89e-01 | 0.0596 |
| 81562 | LMAN2L | LZE21T | Human | Esophagus | ESCC | 1.74e-02 | 1.63e-01 | 0.0655 |
| 81562 | LMAN2L | P2T-E | Human | Esophagus | ESCC | 2.12e-28 | 4.55e-01 | 0.1177 |
| 81562 | LMAN2L | P4T-E | Human | Esophagus | ESCC | 4.17e-17 | 3.72e-01 | 0.1323 |
| 81562 | LMAN2L | P5T-E | Human | Esophagus | ESCC | 8.86e-07 | 8.66e-02 | 0.1327 |
| 81562 | LMAN2L | P8T-E | Human | Esophagus | ESCC | 4.43e-19 | 3.22e-01 | 0.0889 |
| 81562 | LMAN2L | P10T-E | Human | Esophagus | ESCC | 4.32e-19 | 3.36e-01 | 0.116 |
| 81562 | LMAN2L | P11T-E | Human | Esophagus | ESCC | 5.36e-07 | 3.06e-01 | 0.1426 |
| 81562 | LMAN2L | P12T-E | Human | Esophagus | ESCC | 3.12e-24 | 4.38e-01 | 0.1122 |
| 81562 | LMAN2L | P15T-E | Human | Esophagus | ESCC | 1.35e-15 | 3.57e-01 | 0.1149 |
| 81562 | LMAN2L | P16T-E | Human | Esophagus | ESCC | 1.39e-33 | 4.38e-01 | 0.1153 |
| 81562 | LMAN2L | P19T-E | Human | Esophagus | ESCC | 2.67e-06 | 3.62e-01 | 0.1662 |
| 81562 | LMAN2L | P20T-E | Human | Esophagus | ESCC | 7.31e-08 | 1.71e-01 | 0.1124 |
| 81562 | LMAN2L | P21T-E | Human | Esophagus | ESCC | 1.60e-14 | 2.31e-01 | 0.1617 |
| 81562 | LMAN2L | P22T-E | Human | Esophagus | ESCC | 7.05e-30 | 3.77e-01 | 0.1236 |
| 81562 | LMAN2L | P23T-E | Human | Esophagus | ESCC | 5.67e-15 | 3.13e-01 | 0.108 |
| 81562 | LMAN2L | P24T-E | Human | Esophagus | ESCC | 1.47e-13 | 9.27e-02 | 0.1287 |
| 81562 | LMAN2L | P26T-E | Human | Esophagus | ESCC | 3.33e-31 | 3.00e-01 | 0.1276 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:000688815 | Esophagus | ESCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 102/8552 | 130/18723 | 1.73e-14 | 9.22e-13 | 102 |
| GO:000702914 | Esophagus | ESCC | endoplasmic reticulum organization | 65/8552 | 87/18723 | 3.28e-08 | 6.08e-07 | 65 |
| GO:00070308 | Esophagus | ESCC | Golgi organization | 101/8552 | 157/18723 | 1.78e-06 | 2.10e-05 | 101 |
| GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
| GO:000645712 | Liver | HCC | protein folding | 160/7958 | 212/18723 | 1.07e-22 | 1.88e-20 | 160 |
| GO:000688821 | Liver | HCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 100/7958 | 130/18723 | 1.15e-15 | 8.67e-14 | 100 |
| GO:000702911 | Liver | HCC | endoplasmic reticulum organization | 64/7958 | 87/18723 | 3.92e-09 | 1.04e-07 | 64 |
| GO:00070302 | Liver | HCC | Golgi organization | 99/7958 | 157/18723 | 1.54e-07 | 2.85e-06 | 99 |
| GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
| GO:000645718 | Oral cavity | OSCC | protein folding | 154/7305 | 212/18723 | 1.89e-23 | 4.60e-21 | 154 |
| GO:00068888 | Oral cavity | OSCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 97/7305 | 130/18723 | 1.42e-16 | 1.15e-14 | 97 |
| GO:00070294 | Oral cavity | OSCC | endoplasmic reticulum organization | 58/7305 | 87/18723 | 1.59e-07 | 2.61e-06 | 58 |
| GO:00070307 | Oral cavity | OSCC | Golgi organization | 92/7305 | 157/18723 | 4.96e-07 | 7.27e-06 | 92 |
| GO:000645719 | Oral cavity | LP | protein folding | 125/4623 | 212/18723 | 1.62e-26 | 8.45e-24 | 125 |
| GO:004819316 | Oral cavity | LP | Golgi vesicle transport | 141/4623 | 296/18723 | 6.11e-18 | 1.06e-15 | 141 |
| GO:000688814 | Oral cavity | LP | endoplasmic reticulum to Golgi vesicle-mediated transport | 67/4623 | 130/18723 | 3.74e-11 | 2.39e-09 | 67 |
| GO:000702913 | Oral cavity | LP | endoplasmic reticulum organization | 41/4623 | 87/18723 | 4.49e-06 | 9.16e-05 | 41 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LMAN2L | SNV | Missense_Mutation | c.529N>G | p.Pro177Ala | p.P177A | Q9H0V9 | protein_coding | tolerated_low_confidence(0.86) | benign(0.115) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| LMAN2L | SNV | Missense_Mutation | novel | c.560N>T | p.Ser187Leu | p.S187L | Q9H0V9 | protein_coding | tolerated(0.05) | probably_damaging(0.98) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| LMAN2L | SNV | Missense_Mutation | c.970N>A | p.Ala324Thr | p.A324T | Q9H0V9 | protein_coding | tolerated(0.18) | benign(0.039) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| LMAN2L | insertion | Frame_Shift_Ins | novel | c.459_460insG | p.Leu154AlafsTer11 | p.L154Afs*11 | Q9H0V9 | protein_coding | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| LMAN2L | SNV | Missense_Mutation | novel | c.690G>T | p.Lys230Asn | p.K230N | Q9H0V9 | protein_coding | tolerated(0.61) | benign(0.028) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LMAN2L | SNV | Missense_Mutation | rs375965191 | c.701N>T | p.Thr234Met | p.T234M | Q9H0V9 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| LMAN2L | SNV | Missense_Mutation | novel | c.154N>G | p.Lys52Glu | p.K52E | Q9H0V9 | protein_coding | deleterious(0) | possibly_damaging(0.862) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LMAN2L | SNV | Missense_Mutation | c.827N>C | p.Asp276Ala | p.D276A | Q9H0V9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LMAN2L | SNV | Missense_Mutation | c.229N>G | p.Asn77Asp | p.N77D | Q9H0V9 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LMAN2L | SNV | Missense_Mutation | c.712G>T | p.Asp238Tyr | p.D238Y | Q9H0V9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |